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Abstract 
 
Natural products, particularly plants have been an important source of food and 
medicine throughout the history of mankind. High blood pressure has become a 
growing health burden all over the world. There is an obvious need to discover 
better therapeutic agents to tackle this problem. Exploitation of natural products is 
one important option. This thesis describes the results obtained from the 
phytochemical, and bioassay studies, on Nauclea latifolia of Nigerian origin that 
are summarized as follows: 
Chemical studies on the crude methanolic extract of the stem/bark of N. latifolia resulted 
in the isolation of seven new indole alkaloids, latifoliamide A-G (46-52), along with one 
known alkaloid, angustoline (45). The structures of compounds (45-52) were elucidated 
using extensive NMR and mass spectral studies. Compounds (45-52) were evaluated for 
their in vitro renin inhibitory activity. Compounds (45, 46, 49-51) were found to exhibit a 
wide range of anti-renin activity, while 47 and 52 were inactive in the bioassays. Based 
on these bioactivity data, it appears that previously reported anti-hypertensive property of 
this plant in the literature might be due to the presence of these bioactive alkaloids.  
 
 
 
 
 
   
                                                                                                                                           
        iv  iv                                                                                                                                                       
Acknowledgements 
First of all, I am immeasurably grateful to Almighty God for his faithfulness. I wish to 
thank my supervisor, Dr. Athar Ata for his untiring efforts and assistance towards the 
completion of my thesis. My gratitude also goes to the Department of Biology for giving 
me the opportunity to pursue the Bioscience programme. I am particularly grateful to my 
committee members, Dr. Sara Good-Avilla, and Dr. Civetta, Alberto for their assistance 
throughout the thesis work. 
 I thank the staff of Chemistry Dept., particularly Ramin Vakili for their technical 
support. I am grateful to the Faculty of Graduate studies of University of Winnipeg for 
providing me financial support.  Finally, I am indebted to my wife Jane, and my 
wonderful and lovely kids for their moral support, and encouragement throughout the 
duration of my studies. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                           
        v  v                                                                                                                                                       
 
 
 
 
 
 
 
 
“Every simple plant remedy is blessed and gifted by GOD and its Handmaiden nature 
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CHAPTER 1 
   Natural Products Chemistry 
 
1.1 NATURAL PRODUCTS: HISTORICAL BACKGROUND 
Natural products are organic compounds produced by living organisms, including 
plants, marine organisms, and microorganisms, for their survival. These compounds 
exhibit various biological activities that make them an important source of lead 
compounds in drug discovery program.  Plant natural products have provided a 
significant number of lead compounds to the pharmaceutical industry. Recent estimates 
indicate that approximately 60% of anti-cancer and anti-infective agents available on the 
market are of natural product origin. Furthermore, 25% of these pharmaceutical agents 
are of plant origin1. 
For a long time, humans have used plant products to cure disease2,3. The Chinese, 
Indians, and North African cultures have documented the use of plants as medicines4. 
One of the earliest known written documents on herbs is a 4000 year old “Sumerian” clay 
tablet that records remedies for the cure of various illnesses3. The Western world has 
utilized some of this ancient information in discovering many of the currently used 
pharmaceuticals. For instance, William Withering studies of foxglove between 1775 and 
1785 as treatment of dropsy (heart failure) set the standard for pharmaceutical chemistry3. 
Over the years, traditional use of natural products had been intertwined with many 
challenges5 particularly in developing countries, due to several factors, including lack of 
standardization, attribution of results to magic and witchcraft etc. However, it was not 
until early 1800’s that the active principles in medicinal plants were identified, which 
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provided a new direction to the pharmaceutical industry for obtaining lead compounds 
from plants. In 1826, E. Merck identified morphine1 (1), as the first commercially 
available natural product as pain killer from Papaver somniferum. Similarly, other natural 
products like strychnine (2), atropine (3), and colchicine (4) were discovered1. 
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With the development of new chromatographic techniques, and chemical methods to 
elucidate the structures of organic compounds, the active substances of many plants have 
been isolated by the western world6.  Plants provide structural diversity in producing 
natural products, and this diversity makes plants an interesting source to explore for their 
new bioactive lead compounds. In some Asian and African countries, nearly 80% of the 
population depends on traditional medicine for primary health care7. It has been 
estimated that approximately over 250,000 flowering plant species are present world 
wide. Nearly half of these are found in the tropical forests. These plants continue to be a 
rich source of natural products, providing chemists with a rich endowment for the 
discovery of useful drugs, and nutraceuticals8. The search for new biologically active 
compounds is most often based on hints coming from ethnobotany, which prompts 
phytochemical investigation of the particular plant9. For the most part, the discovery of 
new lead bioactive natural products stem from knowledge that their extracts are used to 
treat one or more diseases. The most bioactive extracts are then subjected to bioassay-
directed investigation for the identification of bioactive lead compounds10. Natural 
product scaffolds have also been well recognized as being ‘privileged’ structures in terms 
of their ability to provide novel lead compounds with potential biomedical application. 
Such scaffolds are being used as cores of compound libraries made by combinatorial 
chemistry11. Natural products serve not only as source of important pharmaceutical leads, 
but also help to reveal their novel physiological aspects. For example, digoxin (5), 
isolated from foxglove showed the role of sodium-potassium-ATPase in the maintenance 
of membrane resting potential; morphine (1) explained the role of receptors affected by 
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endogenous opioids; muscarine (6), nicotine (7) and tubocurarane (8) helped to explore 
the different types of acetylcholine receptors12,13. 
An increased awareness and patronage of natural products by people in different parts of 
the world has resulted in a tremendous increase in the amount of plant products in the 
international market, making natural products a huge and potential source of revenue for 
both the developing nations, as well as the developed nations. 
 
 1.2 NATURAL PRODUCTS AND DRUG DISCOVERY 
Natural products have been one of the major providers of lead drug molecules1. The 
use of natural products as an important source of active ingredients for the treatment of 
various medical conditions is historical. This ranges from ethno-botanical applications7, 
to the modern drug research and development35  
1.2.1 Natural Products as Anti-infective Agents 
World wide, infectious disease is the number one cause of death, accounting for 
approximately one-half of all deaths in tropical countries14. For instance, approximately 
60 % of all deaths in children between five and fourteen years of age in India from 2001 
to 2003 were due to infectious diseases15. 
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                         7                                                                                 8 
 
It is estimated that infectious diseases are the underlying cause of death in 8% of the 
deaths occurring in the US15.  The 2004 WHO global burden of disease update indicates 
that death resulting from infectious and parasitic diseases amounted to 16.2% of the total 
causes of death in 200416. 
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The first real breakthrough in the field of anti-infective pharmaceuticals was the 
discovery of penicillin (9), in 1928.  Later on, the discovery of streptomycin (10), helped 
in the treatment of tuberculosis.          
 
                                                           
                                  
                         9                                                                      10 
 
Out of the 90 antibiotics that became commercially available in the United States, or 
were approved world wide, from 1982 to 2002, approximately 79% of these were of 
natural product origin17. The screening for potent antimicrobials has become more intense 
in recent times due to the growing level of drug resistance to many antibiotics. For 
instance, ethanolic extracts of 78 traditional medicinal plants used for infectious disease 
treatment in India have shown anti-bacterial and anti-fungal activity at very low 
concenteration18. Most currently used antifungal drugs are also derived from natural 
products. Examples include polyenes, like nystatin (11), and griseofulvin (12), derived 
from some species of Streptomyces. Echinocandins (13) are synthetic derivative of 
papulacandins, isolated from a strain of Papularia sphaerosperma. Cephalosporins (14), 
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are bactericidal group of antibiotics, first isolated from cultures of Cephalosporium 
acremonium, and interfere with the synthesis of peptidoglycan layer of bacteria cell wall.  
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Although the azoles generally are considered to be synthetic in origin, their drug 
prototype pathway could be traced back to the Streptomyces metabolite azomycin (15)19. 
 
1.2.2 Natural Products as Anti-parasitic Agents 
Parasitic infestation is one of the major health concerns in both developing and 
developed world. Malaria is the most important health problem affecting people in the 
Southern hemisphere. The World Health Organization 2011 “World Malaria Report”, 
estimates that approximately 225 million malaria episodes occurred in 2009 leading to 
approximately 781, 000 deaths20. The discovery of quinine (16) from Cinchona succiruba 
(Rubiaceae) and its subsequent development as an anti-malarial drug represented a 
milestone in the history of anti-parasitic drugs from nature for the treatment of all 
parasitic diseases. Early studies on plant products were followed by an era of  organic 
chemistry that led to the development of the diamidines, like pentamidine (17) and nitro 
heterocyclic anti-protozoal drugs like metronidazole (18)21. 
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1.2.3 Natural products as Anti-cancer Agents 
Cancer is the second leading cause of death in the United States, and other developed 
countries; one out of every four deaths is from cancer. It has also been predicted that  as 
lifestyles changes in developing countries, there would likely be  a significant rise in the 
incidence of cancers that have previously been associated with developed countries, (such 
as breast, colon, prostate and lung cancers),22 in addition to those that are already 
common. Some of the most effective cancer treatments to date are natural products or 
compounds derived from natural products. The search for anti-cancer agents from plant 
sources started in the early 1950s with the discovery and development of the vinca 
alkaloids, vinblastin (19) and vincristine (20)23, originally derived from the periwinkle 
plant Catharanthus roseus, 
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     19 
                             
                                                                       20 
 
and the isolation of the cytotoxic podophyllotoxins (21)24, a non-alkaloid ligan extracted 
from Podophyllum species. These discoveries prompted the National Cancer Institute, 
USA to initiate an extensive world-wide plant collection programme in 196025. Of the 92 
anti-cancer drugs commercially available prior to 1983 in the US, and among world wide 
approved anti-cancer drugs between 1983 and 1994, 60% are of natural product origin25. 
As many as 84% of pediatric oncology patients, 50% of breast cancer patients and 37% 
of prostate cancer patients use complementary and alternative medicine, including 
predominantly herbal approaches26. Plant secondary metabolites also show promise for 
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the cancer chemoprevention, which has been defined as “the use of non-cytotoxic 
nutrients or pharmacological agents to enhance physiological mechanisms that protect the 
organism against mutant clones of malignant cells27. A number of reviews28,29-35  on 
compounds with  anti-cancer activities from natural sources  are present in the literature. 
These are important sources of information that would help identify those compounds 
that would need further exploration.  
                                         
                                                           21 
1.2.4 Role of Natural Products as Anti-viral Agents 
Viral infections constitute one of the most serious health concerns among humans. 
The HIV infection has become a pandemic and has proved to be one of the longest 
infections in history to defy modern medical cure. The medical and economic impact 
particularly in developing countries has been devastating. As of December 2009, more 
than 208 countries worldwide have reported laboratory confirmed cases of pandemic 
influenza H1N1, including at least 11,516 deaths36. Consequently, there has been 
considerable effort over the last 20 years invested into antiviral drug discovery, especially 
in the field of HIV37. Natural product is one important area where scientists continue to 
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explore for anti-infective agents. For instance, betulinic acid, a triterpene of natural 
origin, isolated from various plants, has shown various biologic activities, including anti-
HIV properties38. 
1.2.5 Role of Natural Products in the Treatment of Neurological conditions 
The opiate alkaloids, obtained from Papaver somniferum, are one of the earliest, but 
still relevant central nervous system (CNS) groups of natural product drugs. Other 
compounds include ergot from the fungus, Claviceps purpurea, cocaine, (22) from the 
South American plant, Erythroxylon coca, and the anticholinesterase, physostigmine (23) 
from the Nigerian plant, Physostigma venenosum39. Recently, newer drugs have been 
added to this group. They include:  huperzine (24) from the club moss, Huperzia serrata, 
and galantamine (25) from the plant, Galanthus nivalis, used to treat Alzheimer’s disease. 
Also, epibatidine (26) from the Ecuadorian frog, Epipedobates tricolor, used as a lead 
compound for the development of drugs for pain relief40-42. 
 
 
    
           22          23 
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1.2.6 Role of Natural Products in Immunological, inflammatory and related 
disease Conditions 
The area of immunology and inflammatory conditions has not been left out in the 
impact of natural products. The need for organ transplant in individuals with end stage 
organ conditions, or acute organ damage had witnessed tremendous set back primarily 
due to antigenic variation between the donor and recipient. For this to be minimized one 
has to look for the best possible match, preferably an identical twin, otherwise the 
chances of rejection is be high. The discovery of cyclosporine (27), from the fungus 
Tolypocladium inflatum, and other immunosuppresants43-47, helped in no small means to 
address this issue.  
The discovery of aspirin (28) in 1890s has, and continues to make a tremendous 
impact in different medical conditions particularly cardiovascular conditions, as an anti-
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inflammatory, and as an analgesic47. It has equally served as a lead drug in the discovery 
of other anti-inflammatory agents48, through the discovery of cyclooxygenase isozymes 
COX-1 and 249. 
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1.3 NATURAL PRODUCT AND MODERN BIOTECHNOLOGY 
Man has been applying the principles of biotechnology throughout history, ranging 
from the domestication of animals and plants, to the propagation and preservation of 
desired traits. However, the field of biotechnology was revolutionized following the 
discovery of gene splicing and gene cloning in 1973 by Stanley Cohen and his 
colleagues. Consequently, modern biotechnology has and continues to make impact in 
virtually all aspects of human life.  Since the origin of life, plants have been providing 
man with various needs such as food, and medicine for the treatment of ailments. 
However, the astronomical increase in the human population and his activities, have 
resulted in dwindling natural resources. A great number of different herbs and trees have 
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gone extinct, and many, are already endangered50. Many plants cannot be propagated 
through vegetative methods; plants raised through seeds carry multiple traits and display 
variations in their growth patterns, and yields. Many are affected by a lot of modifiable 
environmental factors and are prone to many disease conditions. These, no doubt pose a 
serious threat to the survival of mankind. In addition, the classical plant-based 
pharmaceutical drug production approach has been hampered by low yields, lack of 
reproducibility, and the high complexity of plant extracts51. 
The emerging field of biotechnology promises to help offer a reasonable solution to some 
of the problems outlined above52. Biotechnological tools are important for multiplication 
and genetic enhancement of the medicinal plants by adopting techniques such as in-vitro 
regeneration and genetic transformations. It can also be harnessed for production of 
secondary metabolites using plants as bioreactors53. Some modern techniques that could 
be of benefit in preserving plant biodiversity and enhancing optimal drug development 
include: 
1. Conservation: This involves the storage of plant genetic material in liquid nitrogen for 
future revival and propagation. This is particularly important in endangered plants and 
those already facing extinction.  
2. Micro propagation: This is another bio-technique which involves the raising of 
multiple plants having the same genetic makeup. This is especially useful for plants in 
high demand, or for those that are slow to cultivate naturally54. Biotechnology enables the 
transfer, manipulation and alteration of plant genetic information. Thus, the cultivation of 
desirable traits allows for functioning improvements in medicinal and aromatic plants, 
such as enhanced medicinal actions or nutritional content55. 
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3. Tissue Culture: Through this technique, isolated plant tissues or organs could be 
monitored under controlled conditions and bioengineered to produce desired plant 
secondary metabolites56,57. 
4. Combinatorial biosynthesis: The combination of genes from different organisms for 
the production of new and desired metabolites.  Combinatorial biosynthesis is a new tool 
in the generation of novel natural products, and for the production of rare and expensive 
natural products such as Artemisinin (29), Pacilitaxel (30), and morphine (1)58. 
                                                    
                29                                                                                          30 
 
These techniques no doubt have different setbacks59, however,  the possibilities of 
overcoming these difficulties is very high judging from the pace of science and 
technological development in the 21st century.  
 
1.4 NATURAL PRODUCTS AND CARDIOVASCULAR CONDITIONS 
Cardiovascular disease (diseases affecting the heart and blood vessels), is one of the 
leading causes of death and disabilities, particularly in the developed world60. 
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Hypertension (High blood pressure) has been described as a major risk factor in different 
cardiovascular diseases, stroke, death, as well as an important cause of end stage kidney 
disease.  The prevalence of hypertension among adult population globally, was estimated 
to be 26% in 200061. It has been estimated that this prevalence will increase by 24% in 
developed countries, and 80% in developing countries by 202561.  
1.4.1 The Role of Renin Angiotensin System in Blood pressure control  
The renin-angiotensin system (RAS) has been recognized as the main physiological 
modulator of blood pressure62. The RAS is a hormonal pathway that maintains the water 
and electrolyte balance of the body and consequently the blood pressure.  Low blood 
volume in the body stimulates the juxtaglomerular cells of the kidney to produce the 
enzyme renin. Renin converts angiotensinogen, a glycoprotein produced by the liver 
cells, to angiotensin I. This is the rate limiting step in the pathway. Angiotensin 
converting enzyme (ACE), produced by the surface covering of the lungs and kidney, 
converts angiotensin I, to angiotensin II. Angiotensin II has a multiple stimulatory effect 
in different organ systems of the body. These actions are modulated through the binding 
of Angiotensin II to either of its receptors AT-1 or AT-263.  Some of these effects include:  
constriction of blood vessels; stimulation of aldosterone production by the adrenal gland 
(aldosterone causes increase in salt and water reabsorption by the kidney); secretion of 
anti-diuretic hormone (ADH) by the pituitary gland (which decreases water removal from 
the body), etc. The overall effect is an increase in blood pressure. Therefore, 
hyperactivity of the RAS system from any source would ultimately result in high blood 
pressure with its negative impact on important organs of the body, like heart, kidney, 
brain etc.  
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Skeggs, and his colleagues in 1957 postulated 3 possible approaches to 
pharmacologically inhibit the renin-angiotensin system: 1) Inhibition of renin, 2) 
inhibition of angiotensin converting enzyme (ACE), 3) Interference with binding of 
angiotensin II to its receptors. Since renin is the initial and rate-limiting substance,” these 
authors observed, “the first approach would be the most likely to succeed64,65, to 
overcome the aforementioned problems. 
 Thus, the discovery of the RAS has made it possible for scientist to design drugs that 
target the major enzymes, and sites that are strategic in this pathway, ultimately helping 
in the control of blood pressure, and indirectly preventing the development of 
complications like renal failure, diabetes, heart failure, etc. 
1.4.2 RAS as an Important Drug Target 
As shown in scheme 1, the RAS system provides three basic points whose blockade 
could provide a means of lowering blood pressure: Direct renin inhibition (DRI); 
Angiotensin converting enzyme inhibition (ACEI); and Angiotensin receptor blockade 
(ARI). 
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Scheme 1.1 Sites of Possible blockade of the RAS cascade 
 
Attempts to block renin, the rate-limiting step in the production of Angiotensin II, using 
monoclonal antibodies, started in the early 1950s66. However, the development of 
clinically effective renin inhibitors has remained elusive because of difficulties in 
identifying suitable agents with the required combination of high affinity for renin’s 
active site and sufficient bioavailability to permit chronic oral administration67. Today, 
about ten angiotensin converting enzyme (ACE) drug inhibitors, including captopril (31), 
ramipril (32) etc, and seven angiotensin receptor blocker (ARB) drugs, including 
candesartan (33), lorsartan (34), are in use as antihypertensive agents. However, after 
more than 50 years of discovering renin and its strategic role in the RAS pathway, only 
one drug, aliskiren (35), was approved by FDA in 2007 as a direct renin inhibitor (DRI). 
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It is also important to note that many of these drugs are synthetically derived. The need to 
discover more DRIs particularly from natural sources is therefore imperative. 
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1.5 MEDICINAL PLANTS AND EMERGING DRUG TARGETS. 
The 20th century has witnessed a monumental advancement in the field of science and 
technology. Consequently, life and its activities have been modified or even changed. 
The field of medicine is one area that has witnessed a continuous change. Drug 
administration and usage is now target specific, and target directed. This is due to the 
identification of specific molecular targets whose deficiency, activity or excess leads to 
the development, or transmission of a disease condition. With the completion of human 
genome project in 2003, and the subsequent sequencing of the genome of many plants 
and animals, pharmacogenomics has become a new face of drug design and 
application68,69. 
While different types of drug targets continue to be discovered, including multi target 
approaches, enzyme targets has and will continue to be a major source of drug target for 
many conditions, whether therapeutic or diagnostic. Enzymes catalyze multistep 
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chemical reactions and achieve phenomenal rate accelerations by matching protein and 
substrate chemical groups in the transition state. Inhibitors that take advantage of these 
chemical interactions are among the most potent and effective drugs known70,71. 
Recently, three new enzyme targets have been validated by FDA approval of new 
enzyme inhibitor drugs. These include mitogen-activated protein kinase, renin, and 
dipeptidyl peptidase IV71. The unique structures and diversity of compounds from natural 
sources makes them good and interesting candidates for the exploitation of these targets 
for the identification of different medicines to handle present and emerging health 
conditions. Many studies targeting different enzymes in the treatment and diagnosis of 
different medical conditions have been done, some of which include: shikimate-pathway 
enzymes72, malaria73, antibacteria74, cancer75,76, and parasitic infestations77.       
Based on the importance of plants in drug discovery process, the present project was 
designed to isolate natural products from N. latifolia and to evaluate them for inhibitory 
activity against renin enzyme. 
 
1.6 Objectives of the Study 
The objectives of this study were: 
1. To isolate pure compounds from N. latifolia 
2. To screen the isolated compounds for anti-renin activity 
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CHAPTER 2 
Phytochemical studies on Nauclea latifolia 
2.1 INTRODUCTION 
N. latifolia, (Rubiaceae) is abundant in Africa and Asia. The plant is known by 
different names in Africa. For instance, it is called ovoro ilu in south east Nigeria. It is a 
straggling shrub or small tree with spreading branches, and could reach a height of 3.5-5 
m. The tree flowers between April and June, and the fruits ripen during the months of 
July to September. Flowers have sweet scented heads and produce red fruits that 
resemble a large hard strawberry. The fruit is edible, with many seeds, and pleasant taste. 
This is one of the important herbal trees used in folk medicine, particularly in different 
parts of Africa. This plant is reported to treat various diseases that include stomach pains, 
fever, diarrhea, helminthic infestation, menstrual irregularities, and diabetes melitus1-8. In 
Nigeria, the bark is also used to treat cough, gonorrhea, and wounds9, 10. 
Recent studies have verified the efficacy of N. latifolia in some of the above mentioned 
ethno-medicinal applications. For instance, when albino mice infected with Plasmodium 
berghei parasites were treated with 500 mg kg-1 of the crude extract of N. latifolia root, 
71.15 % suppression of parasitemia, was observed11.  Aqueous extract infusions and 
decoctions from stems and roots of N. latifolia exhibited in vitro inhibitory activity 
against Plasmodium falciparum strains with IC50 values of 0.6-7.5 µg ml-1. Abbah et al., 
also reported that aqueous extract of N. latifolia root-back 50-200 mg kg-1 per oral, 
significantly increased the threshold for pain perception in mice12. 
Recent phytochemical studies have shown that majority of the biological activities 
exhibited by N. latifolia are mainly due to the presence of high content of monoterpene 
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indol alkaloids, tannins, and terpenoids13,14. These compounds have been shown to 
produce different biological activities including anti-parasitic15,16, anti-helminthic17, anti-
microbial18-24, anti-diabetic25, anti-hypertensive26, and neuropharmacologic activities27,28. 
2.1.1 Previously Reported compounds from Nauclea spp. 
Previous phytochemical studies on the genus Nauclea have resulted in the isolation of 
a number of compounds29,30. For instance, five compounds, naucleamides A—E (36-40), 
monoterpene indole alkaloids were isolated from the bark and wood of N. latifolia13.  
 
 
                                         
                    36 H-16α                                                                           38                          
                    37 H-16β 
 
 
                        
                           39                                                                    40 
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Ata et al., 2009 discovered five known compounds: strictosamide (41), naucleamides A 
(36), naucleamide F (42), quinovic acid-3-O-β-rhamnosylpyranoside (43), and quinovic 
acid 3-O-β-fucosylpyranoside (44), from the crude ethanolic extract of N. latifolia. These 
compounds exhibited GST inhibitory activity with IC50 values in the range of 20.5-143.8 
µM. Among all the isolated compounds, strictosamide (41) was significantly active in 
this bioassay with an IC50 value of 20.5 µM. The bioactivity data of 41, was more or less 
comparable to ethacrynic acid, a standard GST inhibitor (IC50 = 16 µM)31.   
 
                   
                                  41           42 
                                    
                                              
             43 R= α-Rhamnose 
                                      44 R= β- Fucose 
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Given the wide range of reported biological activities of the crude extracts of this plant, 
the present project was designed to isolate pure natural products from N. latifolia, and to 
evaluate their renin inhibitory activity, as this plant has been reported to exhibit anti-
hypertensive properties26. These efforts resulted in the isolation of seven new indole 
alkaloids, namely: latifoliamede A-D (46-52), along with a known alkaloid, angustoline 
(45). These compounds (45-52), were characterized with the help of extensive NMR and 
mass spectral studies. In this chapter, isolation and structure elucidation of compounds 
(45-52) are discussed.                                                 
 
2.2 EXPERIMENTAL 
 
2.2.1 General conditions 
UV spectra were recorded in methanol on a Shimadzu UV-2501, and Shimadzu 
UV2UO PC spectrophotometer. IR spectra were acquired on a Varian 1000 FT-IR 
(Scimitar Series). 1H-NMR, 13C-NMR, and 2D-NMR spectra (COSY, HSQC, HMBC, 
NOESY) spectra were recorded on a Bruker Avance 400 MHz spectrometer using 
deuterated solvents as reference. Mass spectrometer studies were carried out on Varian 
MAC 112 mass spectrometer. Column chromatography was carried out using 60 Å silica 
gel (230-400 mesh), as the stationary phase. Thin layer chromatography (TLC), was 
performed on silica gel 60 F254 aluminum-backed TLC plates (Merck, Germany). 
Developed TLC plates were visualized under UV light using Entela multiband (UV-
254/366nm) lamp. All solvents used in the research project were of ACS reagent grade, 
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and were purchased from Caledon Laboratories Canada. NMR solvents were purchased 
from Cambridge Isotope Laboratories Canada. 
2.2.2 Plant Material  
N. latifolia was collected from Mbaise, Imo state, Nigeria in September 2009. This 
plant was identified by Dr. Biodun Ayodele, Department of Botany, University of Ibadan, 
Nigeria. A voucher specimen (BDCP037) had already been deposited in the herbarium of 
the Biotechnology development and conservation program (BDCP) research centre, 
Nsukka, Nigeria. 
 
2.2.3 Extraction and Isolation of Compounds (45-52) 
  The stem-bark of N. latifolia (3.0 kg) was air dried and cut into smaller pieces 
(Scheme 2.1a). These small pieces were extracted with methanol for three times at room 
temperature. This extract was filtered and rotavaped to afford 250 g yellow colored gum. 
This gum was loaded onto a silica gel column. This column was eluted with hexane-
chloroform (0-100), and chloroform-methanol (0-100). This yielded 159 fractions 
(Scheme 2.1b), which were pooled on the basis of similar Rf values on analytical TLC, to 
afford 13 fractions. Combined fractions 101-106 obtained on elution of silica gel column 
with methanol-chloroform (5:95, 4.98 g), was again loaded onto a silica gel column 
(secondary column). This column was eluted with hexane-dichloromethane (10:90), and 
dichloromethane-methanol (99.9:0.1), to afford 63 fractions which were combined on the 
basis of similar Rf values into 6 fractions (A-F). Preparatory TLC (prep. TLC) of 
combined secondary fractions 59-63 (F) (125.7mg) obtained on elution of the secondary 
column with methanol-dichloromethane (2:98) using methanol-chloroform (7: 93) as a 
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mobile phase yielded compound (50, 14.6 mg), and impure bands: 2b(20.9 mg), 
3b(13.5mg), 4b(16.4 mg). Compound (49), 6.4 mg was purified by the prep. TLC of 
impure band 2b using isopropanol-chloroform (7:93) as a mobile phase.  Band 4b was 
again subjected to prep. TLC using a mixture of isopropanol-chloroform (6:94), in order 
to purify compound (45, 8.0 mg). The compound (47), 3.8 mg, was obtained by the Prep. 
TLC of band 3b using isopropanol- chloroform (6:94) as mobile phase. Prep TLC of 
secondary fractions 46-49 (C) obtained on elution of the secondary column, methanol-
dichloromethane (2:98), and using isopropanol-chloroform (3:97), yielded compound 
(51, 3.2 mg), while prep. TLC of secondary fraction 41-43(A), using isopropanol-
chloroform (3:97), yielded compound (52, 2.1 mg). Fractions 112-113 (1.6 g) of the 
primary column fractions, methanol-chloroform (8: 92) was loaded onto a silica gel 
secondary column and eluted with ethyl acetate-isopropanol (95:5) as mobile phase. Five 
fractions were collected.  Prep. TLC of fraction 3 (50 mg) obtained on elution of the 
silica gel column with, ethylacetate-isopropanol (95:5) using methanol-dichloromethane 
(3.5:96.5) as mobile phase, yielded compounds (46, 8.8 mg) and (48, 15 mg).    
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Scheme 2.1 Flow chart of extraction process. 
a 
b 
c 
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2.3 STRUCTURE ELUCIDATION OF COMPOUNDS (45-52) 
2.3.1 Angustoline (45) 
 
 
            45 
Compound (45) was isolated as a yellow coloured gum. Its IR spectrum displayed intense 
absorption at 3350 (OH), 2950 (CH), 1631 (amide carbonyl) cm-1. The UV spectrum of 
45 showed absorption maxima at 225 and 293 nm. The high-resolution electron-impact 
mass spectrum (HREIMS) of 45 showed a molecular ion peak, m/z at 333.1475, which 
was in agreement with molecular formula C20H19N3O2 (calcd. 333.1477). The 1H-NMR 
spectrum (CDCl3, 400 MHz, Fig. A-22) of 45 showed resonances at δ 7.57 (d, J = 7.2 
Hz), 7.24 (dt, J = 8.0, 7.2 Hz), 7.19 (dt, J = 8.0, 8.0 Hz) and 7.39 (d, J = 8.0 Hz) due to 
the C-9, C-10, C-11, and C-12 protons respectively. The multiplicity pattern of these 
signals indicated the presence of ortho-substituted benzene moiety in this compound. A 
combination of 1H- NMR and UV spectral data suggested that compound (45) had an 
indole like structure. The C-5 and C-6 methylene protons resonated at δ 5.35, 3.03 and 
3.99, 2.99 respectively. A signal at δ 1.53 was ascribed to the C-18 methyl protons.  
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Figure 2.10 1H-NMR Spectrum of 45 
 
The COSY-45o spectrum of 45 (Fig. A-26) showed the presence of four isolated spin 
systems “a-d”. The first spin system “a” was due to the presence of an ortho-substituted 
benzene group. The H-9 (δ 7.57) showed cross-peaks with H-10 (δ 7.24), which in turn 
exhibited vicinal coupling with H-11 (δ 7.19). The later displayed 1H-1H spin correlations 
with H-12 (δ 7.39). The second spin system “b” comprised of H-5 (δ 5.35 and 3.03) and 
H-6 (δ 3.99 and 2.99). Both of these methylene protons exhibited vicinal couplings in the 
COSY-45o spectrum. The spin system “c” started with H-3 (δ 5.60) that showed cross-
peaks with H-14 (δ 3.46 and 1.55). The spin system “d” started with H-18 (δ 1.53) and 
showed cross-peaks with H-19 (δ 4.70). The spin systems “a-d” are shown in Fig. 2.1.  
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Figure 2.11 Spin system “a-d” of 45, as deduced from the COSY 45o spectrum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 COSY 45o spectrum of 45 
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The 13C-NMR spectrum (CDCl3, 100 MHz, Fig. A-23) of 45 showed the resonance of all 
twenty carbons. A combination of DEPT (Figs. A-24, 25) and broad-band 13C-NMR 
spectral data of 45, revealed the presence of eight methine, three methylene, one methyl 
and eight quaternary carbons. Complete 1H and 13C one-bond shift correlations of 45 as 
determined from HSQC spectrum (Fig.A-27), and complete 13C-NMR chemical shift 
assignment of 45   are shown in Table-2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 13C-NMR spectrum of 45 
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Table 2.1. 1H and 13C-NMR data and 1H/13C one-bond shift correlations of 45 as 
determined by HSQC spectrum 
 
Carbon No.             1H-NMR   13C-NMR____ 
    δ (J in Hz)   δ (multiplicitya) 
1.    -    - 
2.    -    131.5 (C) 
3.    5.60    51.2 (-CH-) 
4.    -    - 
5.    5.35    39.4 (CH2) 
    3.03  
6.    3.99    20.8 (CH2) 
    2.99     
7.    -    110.3 (C)   
  
8.    -    126.6 (C) 
9.    7.57, d, (7.2)    120.2 (CH) 
10.    7.24, dt, (8.0, 7.2)   118.6 (CH) 
11.    7.19, dt, (8.0, 8.0)  111.1 (CH) 
12.    7.39, d, (8.0)   122.7 (CH) 
13.    -    136.6 (C) 
14.    3.46    29.7 (CH2) 
    1.55     
15    -    142.0 (C) 
16.    -    124.7 (C) 
17.    8.60    149.7 (CH) 
18.    1.53, d, (6.7)   15.4 (CH3) 
19.    4.70    74.5 (C) 
20.    -    136.6 (C) 
21.    9.30    150.4 (CH) 
22.    -    163.4 (C)  
________________________________________________________ 
 aMultiplicity was determined by DEPT spectrum.  
 
The 1H and 13C NMR data of 45 was nearly identical to those of angustoline, reported in 
the literature32,33. Based on these spectral data, compound (45) was characterized as 
angustoline.  
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2.3.2 Latifoliamide A (46) 
 
                  
            46 
Latifoliamide A (46) was purified as a yellow colored gum. Its IR spectrum displayed 
intense absorption at 3529 (NH) and 3120 (CH) cm-1. The UV spectrum showed 
absorption maxima at 221 and 288 nm. Its molecular formula C20H22N2O2, (calcd. 
332.1681), was provided by HREIMS that exhibited molecular ion peak at m/z 332.1678. 
The 1H-NMR spectrum of 46 (CDCl3, 400 MHz, Fig. A-30), showed resonances of 
ortho-substituted benzene group at δ 7.47 (d, J =7.6 Hz), 7.13(dd, J = 8.0, 7.6 Hz), 7.10 
(dd, J = 8.0, 7.9 Hz), and 7.31 (d, J = 7.9 Hz), due to the C-9, C-10, C-11, and C-12 
protons respectively. A combination of 1H-NMR and UV spectral data suggested that 
compound (46) had indole alkaloid like structure. Two resonances in the 1H-NMR 
spectrum of 46, δ 4.99, 3.0 and 2.90, 2.70 were due to the C-5 and C-6 methylene protons 
respectively. The C-18 methyl and C-19 methine protons appeared at δ 1.48 and 5.54, 
respectively. The COSY-45o spectrum (Fig. A-34) of 46 showed the presence of four 
isolated spin systems “a-d”. The spin system “a” represented an ortho-substituted 
benzene group. In this spin system, H-9 (δ 7.47) showed cross-peaks with H-10 (δ 7.13) 
which in turn exhibited vicinal coupling with H-11 (δ 7.10). The later displayed 1H-1H 
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spin correlations with H-12 (δ 7.31). The spin system “b” was due to the H2-5 (δ 4.99 and 
3.00) and H2 -6 (δ 2.90 and 2.70), as they exhibited vicinal couplings in the COSY 
spectrum. The third spin system “c” started with H-3 (δ 3.0) that showed cross-peaks 
with H2-14 (δ 2.50 and 2.30), which in turn exhibited vicinal coupling with H -15 (δ 
2.45).  The spin system “d” was due to the cross-peaks between H-19 (δ 5.4) and H3-18 
(δ 1.48). All of these spin systems are labeled in Fig. 2.2. 
                            
Figure 2.14 Spin system “a-d” of compound (46), as deduced from the COSY 45o 
spectrum. 
 
The 13C-NMR spectrum (CDCl3, 100 MHz Fig. A-31) of 46 showed the resonance of all 
twenty carbons. A combination of DEPT (Figs. A-32, 33) and broad-band 13C-NMR 
spectrum of 46, revealed the presence of seven methine, four methylene, two methyl and 
seven quaternary carbons in 46. Complete 1H and 13C one-bond shift-correlation of 46 as 
determined from HSQC (Fig. A-35) spectrum and complete 1H, and 13C-NMR chemical 
shift assignment of 46 are shown in Table-2.2. 
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Table 2.2. 1H and 13C-NMR chemical shift assignment of 46 and 1H/13C one-bond shift-
correlations as determined by HSQC 
 
Carbon No.            1H-NMR   13C-NMR____ 
     δ (J in Hz)    δ (multiplicitya) 
1.     -    - 
2.     -    138.2 (C) 
3.     3.00    44.2 (CH) 
4.     -    - 
5.     4.99 
     3.00    46.1 (CH2) 
6.     2.90 
     2.70    29.6 (CH2) 
7.     -    126.8 (C) 
8.     -    127.2 (C) 
9.     7.47, d (7.6)   126.8 (CH) 
10.     7.13, dd, (8.0, 7.6)  120.0 (CH) 
11.     7.10, dd, (8.0, 7.9)  122.2 (CH) 
12.     7.31, d, (7.9)   111.1 (CH) 
13.     -    136.1 (C) 
14.     2.50     
     2.30    21.3 (CH2) 
15.     2.45    35.3 (CH) 
16.     -    66.1 (C) 
17.     1.80    29.4 (CH3) 
18.     1.48, d, (6.9)   20.9 (CH3) 
19.     5.54, d, (7.8)   126.8(C) 
20.     -    132.7 (C) 
21.     4.10 
     4.20    62.1 (CH2) 
22.     -    173.7 (C)  
______________________________________________________________ 
aMultiplicity of each carbon was determined by DEPT spectrum.  
 
These spectral studies led us to propose structure (46), for this new alkaloid.  
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2.3.3 Latifoliamide B (47) 
                                   
     47 
Latifoliamide B (47) was separated as a yellow colored solid. Its IR spectrum displayed 
intense absorption at 3276 (NH), 2925 (CH), and 1628 (amide carbonyl) cm-1. The UV 
spectrum showed absorption maxima at 221 and 293 nm. The HREIMS of 47, showed 
molecular ion at m/z 315.1376, that provided its molecular formula C20H17N3O (calcd. 
315.1372) 
The 1H-NMR spectrum (CDCl3, 400 MHz, Fig. A-15) of 47 showed the resonance of H-
9, H-10, H-11, and H-12 at δ 7.55 (d, J = 7.8 Hz), 7.15 ( dd, J = 7.8, 8.1 Hz),  7.20 (dd, J 
= 8.1, 7.9 Hz) and δ 7.37 (d, J = 7.9 Hz), respectively. Furthermore, the coupling constant 
data suggested the presence of ortho-substituted benzene ring in 47. These 1H-NMR 
spectral data along with the UV spectra indicated this compound was having indole like 
structure as those of previously discussed compounds (45) and (46).  The C-5 and C-6 
methylene protons resonated at δ 5.21, 2.78, and 4.99 respectively. Two signals at δ 6.85 
and 5.55   were due to the H-18 and H2-19, respectively. Four isolated spin systems “a-d” 
were obtained by the careful interpretation COSY- 45o spectrum of 47 (Fig. A-18). The 
first spin system “a” was due to the ortho-substituted phenyl group in which H-9 showed 
cross-peaks with H-10. H-10 exhibited vicinal coupling with H-11. The later displayed 
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1H-1H spin correlations with H-12 (δ 7.37). The second spin system “b” comprised of H-
5 (δ 5.21 and 2.78) and H-6 (δ 4.99). Both of these methylene protons exhibited COSY-
45o interactions with each other. The spin system “c” was traced with H-3 (δ 4.55) that 
showed cross–peaks with H-14 (δ 3.5 and 2.94).  The spin system “d” represented H2-19 
(δ 5.55 and 5.66) and H3-18 (δ 6.85), that exhibited allylic couplings among them. All of 
the aforementioned spin systems are shown in Fig. 2.3.  
 
                                
Figure 2.15 Spin system “a-d” of 47 as obtained from COSY-45o spectrum. 
 
The 13C-NMR spectrum (CDCl3, 100 MHz, Fig. A-16) of 47 showed the resonance of all 
twenty carbons. The DEPT (Fig. A-17) and broad-band 13C-NMR spectral data of this 
compound, revealed the presence of eight methine, four methylene, and eight quaternary 
carbons in this compound. Complete 1H/13C one-bond shift correlation of this compound 
as determined from HSQC spectrum (Fig. A-19), as well as complete 1H and 13C-NMR 
chemical shift assignment of 47 are shown in Table 2.3. 
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Table 2.3. Complete  1H and 13C-NMR chemical shift assignment and  1H/13C one-bond 
shift correlations of 47 as determined by HSQC 
 
Carbon No.    1H     13C____ 
     δ (J in Hz)   δ (multiplicitya) 
1.     -    - 
2.     -    126.9 (C) 
3.     4.55,     51.4 (CH) 
4.     -    - 
5.     5.21, d, 1.84     
     2.78     39.5 (CH2) 
6.     4.99  
     21.1 (CH2) 
7.     -    111.3 (C) 
8.     -    124.5 (C) 
9.     7.55, d, (7.8)   119.0 (CH) 
10.     7.15, dd, (7.8, 8.1)  120.4 (CH) 
11.     7.20, dd, (8.1, 7.9)  120.4 (CH) 
12.     7.37, d, (7.9)   110.5 (CH) 
13.     -    131.7 (C) 
14.     3.50, d, (3.96) 
     2.94    32.1 (CH2) 
15.     -    141.6 (C) 
16.     -    119.4 (C) 
17.     9.22    149.7 (CH) 
18.     6.85, dd, (11.3, 17.6)  136.8 (CH) 
19.     5.55d (11.3)   123.0 (CH2) 
     5.66, d, (17.6)     
20.     -    142.2 (C) 
21.     8.76    150.4 (CH) 
22.     -    163.7 (C)  
______________________________________________________________ 
aMultiplicity of each carbon was determined by DEPT experiment.  
 
Based on these spectral studies, structure 47, was assigned to this new alkaloid. 
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2.3.4 Latifoliamide C (48) 
 
                 
           
            48 
 
Latifoliamide C (48) was isolated as a greenish-yellow colored compound. Its IR 
spectrum displayed intense absorption at 3339 (OH), and 2944 (CH) cm-1. The UV 
spectrum showed absorption maxima at 224 and 295 nm, indicating the presence of 
indole moiety. The HREIMS of 48 provided its molecular formula C21H24N2O3 (m+ m/z 
352.1783, calcd. 352.1787) 
The 1H-NMR spectrum (CDCl3 400 MHz, Fig. A-38) of 48 showed signals at δ 7.47 (d, J 
=7.7 Hz), 7.14 (dd, J = 7.7, 8.0 Hz), 7.03 (dd, J = 8.0, 7.9 Hz)   and 7.30 (d, J = 7.9 Hz) 
due to the C-9, C-10, C-11, and C-12 protons of the ortho-substituted phenyl groups, 
respectively. These chemical shift values and UV spectral data were consistent with the 
previously discussed compounds 45-47, and indicated the presence of indole alkaloid. 
Resonances at δ 4.80, 2.90 and 2.80, 2.60 were ascribed to the C-5 and C-6 methylene 
protons respectively. The C-18 methyl and C-19 methine protons resonated at δ 1.49 and 
5.70 respectively. The COSY-45o spectrum like previously described compounds showed 
the presence of four partial structures “a-d”. The partial structure “a” was due to the 
presence of an ortho-substituted phenyl group as H-9 showed cross-peaks with H-10 that 
exhibited vicinal couplings with H-11. The later displayed COS-45o interaction with H-
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12 (δ 7.30). The second spin system “b” comprised of H-5 (δ 4.80 and 2.90) and H-6 (δ 
2.80 and 2.60), as these protons exhibited COSY-45o interaction with each other. The 
spin system “c” consisted of H-3 (δ 4.97) that showed cross-peaks with H2-14 (δ 3.62 and 
2.78). The later exhibited vicinal couplings with H-15 (δ 2.76).  The spin system “d” was 
traced with the cross-peaks between H-19 (δ 5.70) and H3-18 (δ 1.49). Allylic couplings 
of H2-21 (δ 4.18, and 3.66), with H-19 were also observed in the COS-45o spectrum of 
this compound. 
 
                          
Figure 2.16 Partial structures “a-d” deduced from the COS-45o spectrum of 48. 
 
The 13C–NMR spectrum (CDCl3, 100 MHz, Fig. A-39) of 48, showed the resonance of 
all twenty one carbons. A combination of DEPT (Figs. A-40, 41) and broad-band 13C-
NMR spectra of the alkaloid revealed the presence of eight methine, four methylene, two 
methyl and seven quaternary carbons in it. The HSQC spectrum (Fig. A-42) was used to 
establish 1H/C13 one-bond shift correlations of protonated carbons. In this spectrum, H-3 
(δ 4.97) was found to be bonded with C-3 (δ 51.0). Similarly,  H-9 (δ 7.47 ), H-10 (δ 
7.14), H-11 (δ 7.03) and H-12 (δ 7.30) exhibited 1H/C13 one-bond shift correlations with 
C-9 (δ 110.0), C-10 (δ 119.7), C-11 (δ 121.7) and C-12 (δ 111.3), respectively. Complete 
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1H/C13 one-bond shift correlations of all hydrogen bearing carbons in 48, are shown in 
Table 2.4. Complete 1H and 13C-NMR chemical shift assignments are presented in Table 
2.4 
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Table 2.4. Complete 1H and 13C-NMR chemical shift assignment of 48 and 1H/13C one-
bond shift correlations as determined from HSQC spectrum 
 
Carbon No.               1H    13C__________ 
    δ (J in Hz)   δ (multiplicitya)  
1.    -    - 
2.    -    132.7 (C) 
3.    4.97    51.0 (CH) 
4.    -    - 
5.    4.80 
    2.90    92.9 (CH2) 
6.    2.80 
    2.60    21.0 (CH2) 
7.    -    110.5 (C) 
8.    -    126.8 (C) 
9.    7.47, d, (7.7)   110.0 (CH) 
10.    7.14, dd, (7.7, 8.0)  119.7 (CH) 
11.    7.03, dd, (8.0, 7.9)  121.7 (CH) 
12.    7.30, d, (7.9)   111.3 (CH) 
13.    -    136.3(-C-) 
14.    3.62 
    2.78    29.5 (CH2) 
15.    2.76    31.1 (CH) 
16.    2.76    46.2 (CH) 
17.    9.97    92.9 (CH) 
18.    1.49, d, (6.9)   12.7 (CH3) 
19.    5.70, q, (6.9)   130.8 (C) 
20.    -    138.5 (C) 
21.    4.18 
    3.66    65.7 (CH2) 
22.    -    174.0 (C)  
     _________________________________________________________  
aMultiplicity of each carbon was determined by DEPT spectrum.   
 
These spectral studies led us to propose structure (48) for this new alkaloid. 
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2.3.5 Latifoliamide D (49) 
                             
            49 
 
Compound (49) was isolated as a yellow colored gum. Its IR spectrum displayed intense 
absorption at 3319 (NH), 2941(CH), and 1670 (amide carbonyl) cm-1. The UV spectrum 
of 49 showed absorption maxima at 220 and 289 nm, indicating the presence of indole 
chromophore. The molecular formula, C19H17N3O (calcd. 303.1374) by the HREIMS, 
M+ m/z 303.1377. 
The 1H-NMR spectrum (DMSO, 400 MHz, Fig. A-9) of 49 showed signals at δ 7.48 (d, J 
= 7.6 Hz), 7.03 (dt, J = 7.6, 7.0 Hz), 7.12 (dt, J = 8.1, 7.0 Hz) and 7.39 (d, J = 8.1 Hz) 
due to the C-9, C-10, C-11, and C-12 protons. The multiplicity pattern indicated the 
presence of ortho-substituted benzene moiety in 49. These signals along with the UV 
spectral data also suggested that compound (49) had indole-like structure. The C-5 and C-
6 methylene protons resonated at δ 5.05, 2.86 and 3.00, 1.56 respectively. A three proton 
singlet at δ 2.0 was due to the C-18 methyl proton. The COS-45o spectrum (Fig. A-9) of 
49 revealed the presence of three partial structures “a-c”. The first partial structure “a” 
was due to the ortho-substituted phenyl moiety. H-9 (δ 7.48) of partial structure “a” 
showed vicinal couplings with H-10 (δ 7.03) which in turn exhibited vicinal coupling 
with H-11 (δ 7.12). The later displayed 1H-1H spin correlations with H-12 (δ 7.39). The 
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second partial structure “b” comprised of H2-5 (δ 5.05 and 2.86) and H2-6 (δ 3.00 and 
1.56). Both of these methylene protons exhibited vicinal couplings with each other. The 
third partial structure “c” started with H-3 (δ 5.05) that showed cross-peaks with H2-14 (δ 
3.80 and 2.98).  
                                        
 Figure 2.17 Partial structures “a-c” obtained from the COSY 45o spectrum of 49 
 
The 13C–NMR spectrum (DMSO, 100 MHz, Fig. A-10) of 49 showed the resonance of 
all nineteen carbons. A combination of DEPT (Fig. A-11) and broad-band 13C-NMR 
spectral data of 49, suggested the presence of seven methine, three methylene, one methyl 
and eight quaternary carbons. The HSQC experiment (Fig. A-13) was performed to 
establish 1H and 13C one-bond correlations of all hydrogen-bearing carbons. Complete 1H 
and 13C one-bond shift correlation of 49 as determined from HSQC spectrum and 
complete 1H and 13C-NMR chemical shift assignment of 49 are shown in Table-2.5 
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Table 2.5. Complete 1H and 13C-NMR chemical shift assignment as well as  1H/13C one-
bond shift correlations of 49 as determined from  HSQC spectrum 
 
Carbon No.              1H    13C__________ 
    δ (J in Hz)   δ (multiplicitya)  
1.    -    - 
2.    -    126.5 (C) 
3.    5.05    51.2 (CH) 
4.    -    - 
5.    5.05     
    2.86    40.2 (CH2) 
6.    3.00 
    1.56    20.9 (CH2) 
7.    -    111.6 (C) 
8.    -    152.2 (C) 
9.    7.48, d, (7.6)   119.1 (CH) 
10.    7.03, dt, (7.6, 7.0)  110.5 (CH) 
11.    7.12, dt, (8.1, 7.0)   126.5 (CH) 
12.    7.39, d, (8.1)   118.3 (CH) 
13.    -    133.6 (-C-) 
14.    3.80    31.1 (CH2) 
    2.98     
15.    -    133.6 (C) 
16.    -    110.5 (C) 
17.    8.90    152.2 (CH) 
18.    2.0    25.30 (CH3) 
19.    -    110.5 (CH) 
20.    8.56    143.9 (-CH-) 
21.    -    163.4 (C)  
_________________________________________________________ 
aMultiplicity was determined by DEPT experiment.  
 
Based on these spectral studies, structure (49) was established for this new alkaloid. 
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2.3.6 Latifoliamide E (50) 
 
 
                                           
       50     
 
Latifoliamide E (50) was purified as a yellow colored gum. Its IR spectrum displayed 
intense absorption at 3283 (OH), 2922 (CH), and 1615 (amide carbonyl) cm-1. The UV 
spectrum showed absorption maxima at 223 and 290 nm, indicating the presence of 
indole functionality. Its molecular formula, C22H23N3O3 (calcd. 377.1739), was 
established by HRIES that showed molecular ion peak at m/z 377.1742.  
The 1H-NMR spectrum (DMSO, 400 MHz, Fig. A-1) of 50 showed signals at δ 7.38 (d, J 
= 7.6 Hz), 7.04 (dd, J = 8.0, 7.6 Hz), 6.99 (dd, J = 8.0, 8.0 Hz), 7.33 (d J = 8.6 Hz), due 
to the C-9, C-10, C-11, and C-12 protons of ortho-substituted phenyl moiety. These 1H-
NMR signals along with UV spectral data suggested the indol-like structure of 50. The C-
5 and C-6 methylene protons resonated at δ 2.95, 4.78 and 2.95, 3.80, respectively. The 
C-18 methyl and C-19 methine protons resonated at δ 1.46 and, 5.41 respectively. The 
COS-45o spectrum of 50 (Fig. A-5) showed the presence of four isolated spin systems “a-
d” in this new alkaloid. The first spin system “a” was due to the presence of an ortho-
substituted phenyl group. H-9 (δ 7.38) of spin system “a” showed cross-peaks with H-10 
(δ 7.04) which in turn exhibited vicinal coupling with H-11 (δ 6.99). The cross-peaks 
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between H-11 and H-12 (δ 7.33) were also observed in the COSY-45o spectrum. The 
second spin system “b” was comprised of H2-5 (δ 2.95, 4.78) and H2-6 (δ 2.95 and 3.80) 
as both of these methylene protons showed vicinal couplings. The spin system “c” started 
with H-3 (δ 5.29) that showed cross-peaks with H2-14 (δ 2.96 and 3.31). The spin system 
“d” was observed in the COSY-45o spectrum as H-19 (δ 5.41) showed cross-peaks with 
each other.  
 
                                       
Figure 2.18 Spin systems “a-d” of compound (50) obtained from the COSY-45o 
spectrum. 
 
The 13C-NMR spectrum (CDCl3, 100 MHz) of 50 (Fig. A-2) showed the resonance of all 
twenty two carbons. The C-22 amide carbonyl resonated at δ 168.0. The C-19 resonated 
at δ 60.5.  A combination of DEPT (Figs. A-3,4) and broad-band 13C-NMR spectral data 
of 50, revealed the presence of seven methine, three methylene, two methyl and ten 
quaternary carbons. The HSQC experiment (Fig. A-6) helped to establish 1H/13C one-
bond shift correlations. Complete 1H and 13C-NMR chemical shift assignment of 50 and 
1H/13C one-bond shift correlations of 50 as determined from HSQC spectrum are shown 
in Table-2.6. 
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Table 2.6. Complete 1H and 13C-NMR chemical shift assignment of 50 and 1H/13C one-
bond shift correlations as determined from HSQC spectrum 
 
Carbon No.               1H    13C__________ 
     δ (J in Hz)   δ (multiplicitya)  
1.     -    - 
2.     -    126.9 (C) 
3.     5.29    53.6 (CH) 
4.     -    - 
5.     2.95 
     4.78    42.3 (CH2) 
6.     2.95 
     3.80    30.6 (CH2) 
7.     -    111.2 (C) 
8.     -    126.9 (C) 
9.     7.38, d, (7.6)   124.5 (CH) 
10.     7.04, dd, (8.0, 7.6)  117.5 (CH) 
11.     6.99, dd, (8.0, 8.0)  118.5 (CH) 
12.     7.33, d, (8.6)   114.2 (CH) 
13.     -    134.8 (C) 
14.     2.96 
     3.31    30.6 (CH2) 
15.     -    135.8 (C) 
16.     -    119.4 (C) 
17.     -    134.9 (C) 
18.     1.46    11.5 (CH3)  
19.     5.41    60.5 (CH) 
20.     -    136.4 (C) 
21.     8.5    120.8 (CH) 
22.     -    168.0 (C)  
CH3C=O    2.03    20.6 
CH3C=O     -    206.0 (C) 
________________________________________________________________ 
aMultiplicity was determined by DEPT spectrum.  
   
  
A combination UV, MS, IH, 13C, COSY HSQC and HMBC spectral data led us to assign 
structure (50) to this new alkaloid. 
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2.3.7 Latifoliamide F (51) 
              
                   51 
 
Latifoliamide F (51) was obtained as a yellow colored compound. Its IR spectrum 
displayed intense absorption at 3338 (NH), 2945 (CH) and 1654 (amide carbonyl) cm-1. 
The UV spectrum showed absorption maxima at 221 and 289 nm, indicating the presence 
of indole nucleus. Its HREIMS displayed a molecular ion peak at m/z 308.1527 that 
provided molecular formula C19H20N2O2 (calcd. 308.1525). 
The 1H-NMR spectrum (CDCl3, 400 MHz, Fig. A-50) of 51 showed signals at δ 7.45 (d, 
J = 8.0 Hz), 7.26 (dt, J = 8.0, 7.96 Hz)   7.14 (dt, J = 8.0, 7.96 Hz) and 7.52 (d, J = 7.8 
Hz) due to the C-9, C-10, C-11, and C-12 protons of the ortho-substituted phenyl moiety. 
These 1H-NMR data along with UV spectral data suggested that compound (51) had 
indole-like structure. Signals at δ 5.06, 2.60 and 2.96, 2.46 were due to the C-5 and C-6 
methylene protons respectively. The C-18 methyl protons resonated at δ 1.35. The COS-
45o spectrum of 51 (Fig. A-54) helped to establish partial structures “a-c”. The first 
partial structure “a” was due to the presence of an ortho-substituted benzene group. H-9 
(δ 7.45) of partial structure “a” showed cross-peaks with H-10 (δ 7.26) which in turn 
exhibited vicinal coupling with H-11 (δ 7.14). The later displayed 1H-1H spin correlation 
with H-12 (δ 7.52). The second partial structure “b” was consisted of H2-5 (δ 5.06 and 
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2.60) and H2-6 (δ 2.96 and 2.46). Both of these methylene protons exhibited COSY-45o 
interaction with each other. The third partial structure “c” started with H-14 (δ 3.00) that 
showed cross-peaks with H-15 (δ 2.96). Partial structure “a-c” are shown in Fig. 2.7. The 
13C-NMR spectrum (CDCl3, 100 MHz, Fig. A-51) showed the resonance of all nineteen 
carbons.  
 
    
Figure 2.19 Spin system “a-d” of compound (51), as deduced from the COSY 45o 
spectrum. 
 
The DEPT experiments (Figs. A-52, 53) were performed in order to establish the 
multiplicity of each carbon signal. The HSQC experiment (Fig. A-55) was performed in 
order to establish 1H / 13 C one-bond correlations of all pronated carbons. Complete 1H 
and 13C-NMR chemical shift assignment of 51 as determined from HSQC spectrum and 
1H /13C one-bond shift correlations of all hydrogen bearing carbons as determined by 
HSQC spectrum are shown in Table 2.7. 
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Table 2.7. Complete 1H and 13C-NMR chemical shift assignment of 51 and 1H/13C one-
bond shift correlations as determined from HSQC spectrum 
 
Carbon No.              1H    13C__________ 
    δ (J in Hz)   δ (multiplicitya)  
1.    -    - 
2.    -    127.6 (C) 
3.    5.05    53.6 (CH) 
4.    -    - 
5.    5.06 
    2.60    43.3 (CH2)    
6.    2.96 
    2.46    21.1 (CH2) 
7.    -    111.4 (C) 
8.    -    122.2 (C) 
9.    7.45, d, (8.0)   118.3 (CH) 
10.    7.26, dt, (8.0, 7.96)  120.0 (CH) 
11.    7.14, dt, (8.0, 7.96)  123.4 (CH) 
12.    7.52, d, (7.8)   135.9 (CH) 
13.    -    164.3 (CH) 
14.    3.00 
    3.00    43.3 (CH2) 
15.    2.96    53.7 (CH) 
16.    3.03    56.0 (CH) 
17.    -    111.4 (CH3) 
18.    1.35    14.1 
19    4.56    80.0 (CH2) 
    3.96     
20.    8.10    148.8 (C) 
21.    -    164.3 (C)  
_________________________________________________________ 
aMultiplicity was determined by HSQC spectrum.  
 
These spectroscopic studies led us to characterize compound (51) as latifoliamide D.  
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2.3.8 Latifoliamide G (52) 
 
            52 
 
Latifoliamide G (52) was isolated as a yellow colored solid. Its IR spectrum displayed 
intense absorption at 3703 (OH) and 1236 (amide carbonyl) cm-1. Its UV spectrum 
showed absorption maxima at 225 and 293 nm, indicating the presence of indole moiety. 
The HREIMS of 52, provided its molecular formula C22H23N3O3 (calcd. 377.1739), as it 
exhibited the molecular ion peak at m/z 377.1742 
The 1H-NMR spectrum (CDCl3, 400 MHz, Fig. A-45), of 52 showed signals at δ 7.49 (d, 
J = 7.8 Hz), 7.13 (dt, J = 7.2, 6.9 Hz), 7.20 (dt, J = 8.0, 6.9 Hz) and 7.40 (d, J = 8.0 Hz) 
due to the C-9, C-10, C-11, and C-12 protons respectively. This multiplicity pattern is 
characteristic of ortho-substituted phenyl group. These 1H data along with UV spectral 
data as discussed previously suggested that compound (52) was a member of indole 
alkaloid. Resonances at 5.00, 3.00 and 3.95, 1.96 were due to the C-5 and C-6 methylene 
protons respectively. A three proton doublet at δ 1.48 was due to the C-18 methyl proton.  
O-methyl protons appeared at δ 3.50. A careful interpretation of the COSY spectrum 
(Fig. A-47) of compound (52) revealed the presence of four isolated spin systems “a-d”. 
The first spin system “a” was due to the ortho-phenyl moiety present in 52. H-9 (δ 7.49) 
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showed cross-peaks with H-10 (δ 7.13) that in turn showed COSY-45o interactions with 
H-11 (δ 7.20). The later exhibited vicinal couplings with H-12 (δ 7.40). The second spin 
system “b” was due to the C-5 (δ 5.00, 3.00) and C-6 (δ 3.95, 1.96) methylene protons. 
The third spin system “c” started with H-3 (δ 4.99) that showed cross-peaks with H2-14 δ 
3.00, and 1.99. The fourth spin system “d” was due to 2-hydroxy ethyl group in which H-
19 (δ 3.98) showed cross-peaks with H3-18 (δ 1.48).  
 
     
Figure 2.20 Spin systems “a-d” of compound (52) obtained from the COSY-45o 
spectrum 
 
The 13C-NMR spectrum (CDCl3, 100 MHz, Fig. A-46) showed the resonance of all 
twenty-two carbons. The C-22 resonated at δ 164.6. A downfield aliphatic C-19 appeared 
at δ 72.0. Its downfield chemical shift value was indicative of the presence of a geminal 
hydroxyl group. A combination of DEPT and broad-band 13C-NMR spectral data of 52 
revealed the presence of seven methine, three methylene, two methyl, and ten quaternary 
carbons in 52. The HSQC experiment (Fig. A-48) was performed to establish 1H/13C one-
bond correlations, and this data is presented in Table 2.8. Complete1H and 13C-NMR 
chemical shift assignments are listed in Table 2.8.  
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Table 2.8. Complete 1H and 13C-NMR chemical shift assignment of compound (52) as 
well as HSQC spectral data 
 
Carbon No.              1H    13C__________ 
    δ (J in Hz)   δ (multiplicitya)  
1.    -    - 
2.    -    127.7 (C) 
3.    4.99    53.3 (CH) 
4.    -    - 
5.    5.00 
    3.00    43.3 (CH2) 
6.    3.95 
    1.96    19.4 (CH2) 
7.    -    111.5 (C) 
8.    -    122.3 (C) 
9.    7.49, d, (7.8)   118.3 (CH) 
10.    7.13, dt, (7.2, 6.9)  120.6 (CH) 
11.    7.20, dt, (8.0, 6.9)  120.0 (CH) 
12.    7.40, d, (8.0)   132.5 (CH) 
13.    -    135.9 (C) 
14.    3.00 
    1.99    56.4 (CH2) 
15.    -    150.6 (C) 
16.    -    127.5 (C) 
17.    9.80    132.5 (CH) 
18.    1.48, d, (6.3)   19.4 (CH3) 
19.    3.98    72.0 (CH) 
20.    -    111.5 (C) 
21.    3.5    150.6 (C) 
22.    -    164.5 (C)  
_________________________________________________________ 
aDEPT spectrum was used to establish multiplicity at carbon signals.  
 
Based on these spectral studies, structure (52) was assigned to this new alkaloid.  
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Angustoline (45); greenish-yellow colored gum, 8.0 mg; UV (MeOH): λmax 225, 293 
nm; IR (MeOH): νmax 3350 (OH), 2950 (CH), 1631 (amide carbonyl) cm-1; HREIMS 
m/z 333.1475 (calcd. for C20H19N3O2, 333.1477); 1H-NMR (CDCl3, 400M Hz) = see 
Table 2.1; 13C-NMR (CDCl3, 100 MHz) = see Table 2.1 
 
Latifoliamide A (46); yellow colored solid, 8.8 mg; UV (MeOH): λmax 221, 288 nm; IR 
(MeOH): νmax 3529 (NH) and 3120 (CH) cm-1; HREIMS m/z 332.1678 (calcd. for 
C20H22N2O2, 332.1681); 1H-NMR (CDCl3, 400M Hz) = see Table 2.2; 13C-NMR (CDCl3, 
100 MHz) = see Table 2.2 
 
Latifoliamide B (47); yellow colored gum, 3.8 mg; UV (MeOH): λmax 221, 293 nm; IR 
(MeOH): νmax 3276 (NH), 2925 (CH), and 1628 (amide carbonyl) cm-1; HREIMS m/z 
315.1376 (calcd. for C20H17N3O, 315.1372); 1H-NMR (CDCl3, 400M Hz) = see Table 
2.3; 13C-NMR (CDCl3, 100 MHz) = see Table 2.3 
 
Latifoliamide C (48); greenish-yellow colored solid, 15 mg; UV (MeOH): λmax 224, 295 
nm; IR (MeOH): νmax 3339 (OH), and 2944 (CH) cm-1; HREIMS m/z 352.1783 (calcd.  
for C21H24N2O3, 352.1787); 1H-NMR (CDCl3, 400M Hz) = see Table 2.4; 13C-NMR 
(CDCl3, 100 MHz) = see Table 2.4 
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Latifoliamide D (49); yellow colored gum, 6.4 mg; UV (MeOH): λmax 220, 289 nm; IR 
(MeOH): νmax 3319 (NH), 2941(CH), and 1670 (amide carbonyl) cm-1; HREIMS m/z 
303.1377 (calcd. for C19H17N3O, 303.1374); 1H-NMR (DMS, 400M Hz) = see Table 2.5; 
13C-NMR (CDCl3, 100 MHz) = see Table 2.5 
 
Latifoliamide E (50); yellow colored solid, 14.6 mg; UV (MeOH): λmax 223, 290 nm; IR 
(MeOH): νmax 3283 (OH), 2922 (CH), and 1615 (amide carbonyl) cm-1; HREIMS m/z  
377.1742 (calcd. for C22H23N3O3, 377.1739); 1H-NMR (DMSO, 400M Hz) = see Table 
2.6; 13C-NMR (CDCl3, 100 MHz) = see Table 2.6 
 
Latifoliamide F (51); yellow colored gum, 3.2 mg; UV (MeOH): λmax 221, 289 nm; IR 
(MeOH): νmax 3338 (NH), 2945 (CH) and 1654 (amide carbonyl) cm-1; HREIMS m/z 
308.1527 (calcd. for C19H20N2O2, 308.1525); 1H-NMR (CDCl3, 400M Hz) = see Table 
2.7; 13C-NMR (CDCl3, 100 MHz) = see Table 2.7 
 
Latifoliamide G (52); yellow colored solid, 2.1 mg; UV (MeOH): λmax 225, 293 nm; IR 
(MeOH): νmax 3703 (OH) and 1236 (amide carbonyl) cm-1; HREIM m/z 377.1742 
(calcd. for C22H23N3O3, 377.1739); 1H-NMR (CDCl3, 400M Hz) = see Table 2.8; 13C-
NMR (CDCl3, 100 MHz) = see Table 2.8 
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CHAPTER 3 
       Renin Inhibitory Assay 
3.1 INTRODUCTION 
Hypertension is an abnormal and sustained elevation in blood pressure, beyond what  
is normal for the age of an individual. The incidence of hypertension is increasing day by 
day and has now become a global burden. In 2000, 26% of the adult population globally, 
were diagnosed with hypertension. The number of adults with hypertension in 2025 are 
projected to increase by about 60% to a total of 1.56 billion (1.54-1.58 billion)1,2.  
Hypertension has been identified as the third major factor for disability adjusted life years 
(DALY)3. It can primarily affect the heart leading to many heart complications including 
heart failure, or has secondary effect on other body organs and systems like brain 
(stroke), kidneys ( kidney failure), etc. 
3.1.1  The Renin Angiotensin System and its role in blood pressure regulation 
The renin-angiotensin system (RAS) plays a pivotal role in controlling and 
maintaining arterial blood pressure, tissue perfusion and body water4. Attempts to find 
effective ways to treat hypertension led researchers to discover the methods by which the 
body regulates blood pressure. The RAS was discovered in 1898 by Tigerstedt and 
Bergmann by showing the existence of heat labile substance in crude extracts of rabbit 
kidney. This extracts caused a sustained increase in arterial blood pressure5.  
Skeggs and his colleagues in 1957 postulated three possible approaches to 
pharmacologically inhibit the RAS pathway.  (i) Inhibition of angiotensin converting 
enzyme (ACE); (ii) Inhibition of renin, and (iii) interfering with angiotensin-II binding to 
its receptors. Since the step of this cascade, catalyzed by renin is the rate limiting step, 
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these researchers noted that this step is the most critical in the entire pathway6,7.  The 
pharmacological inhibition of the enzymes, and receptors involved in the RAS pathway 
(Scheme 3.1), has thus offered a very important target for the discovery of drugs for 
treating not only heart and blood vessel diseases, but also other conditions like kidney 
and liver disease8. 
      
DRIs – Direct renin inhibitors 
ACEIs – Angiotensin converting enzyme inhibitors 
ARBs – Angiotensin receptor blockers 
Scheme 3.1. RAS cascade and blood pressure regulation 
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3.1.2   The Enzyme Renin 
Renin belongs to the aspartic proteases family of enzymes which also includes the 
enzymes pepsin, cathepsin, and chymosin9. It is made up of 340 amino acid residues and 
it is highly specific for its substrate. It is made up of 2 homologous lobes, with the active 
sites residing between the two lobes. The catalytic activity of the enzyme is due to the 2 
aspartic acid residues (32 and 215) provided by each lobe. The active site can 
accommodate 7 amino acid units of the substrate angiotensinogen, and cleaves the 
Leu10-val11 peptide bond within angiotensinogen to generate angiotensin I (A-I). The 
reaction catalyzed by renin is the rate-limiting step in A-II formation. Both of these forms 
(A-I & A-II) cannot be synthesized in the absence of rennin6. 
Renin is produced by the epithelial cells of the kidney. It is released when the kidney 
senses decrease in blood volume, extracellular volume, and arterial blood pressure. Renin 
acts on angiotensinogen, an alpha-2 globulin, with 452 amino acids, converting it to 
angiotensin I (10 amino acids). In the next step, angiotensin converting enzyme, 
produced from the lung and the kidney, converts angiotensin I to angiotensin II (8 amino 
acids). Angiotensin II causes the constriction of blood vessels and has a stimulatory effect 
on many organ systems of the body. The net effect is salt and water retention in the body 
and that causes increase in blood pressure. 
3.1.3   Blood pressure medications: Historical background 
Over the years, scientists have made spirited efforts in discovering effective ways of 
treating hypertension. However, early attempts for the treatment of hypertension using 
drugs started after 1945. This began with the introduction of reserpine (53) in 1953. 
Reserpine was derived from the snakeroot plant Rauwolfia serpentine, used by Indians in 
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folk medicine. The active ingredient was then isolated and named reserpine, and was 
synthesized in 1956 by Robert Burns Woodward. Reserpine was the first antihypertensive 
drug to achieve wide clinical use because of its nearly universal effectiveness10. The 
thiazide diuretic (benzothiazide) (54), which acts by increasing water excretion, was 
introduced in 1957, and the beta blockers (propranolol) (55), in 1964.  The calcium 
channel blockers (e.g. verapamil) (56), which blocks the channels that carry calcium to 
the heart was introduced in the 1980s.  
Studies on the discovery of drugs targeting the RAS pathway started with the 
development of angiotensin converting enzyme inhibitor captopril (57) by Cushman and 
his colleagues in 197711. This was followed by the discovery of ramipril and enalapril 
which are pro drugs. The first angiotensin receptor blocker losartan (58) was discovered 
in 1986, and is the prototype from which all the other ARBs were derived12. It was 
approved by FDA in 1995, as the first non-peptide angiotensin II receptor blocker anti-
hypertensive. 
 
 
       
                             53                                                                                   54 
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Despite the promise of ACE inhibitors and Angiotensin receptor blockers (ARBs,) nearly 
70% of patients still fail to achieve adequate BP control, and the desired improvements in 
cardiovascular morbidity and mortality have also failed to materialize. Since both ACE 
inhibitors and ARBs interrupt the negative feedback loop of the renin system, renin can 
still be released. Therefore, these compounds do not completely block the RAS, which 
impedes a full effect in reducing BP in hypertension13. 
Direct inhibition of renin has been proposed as a therapeutic option for the treatment of 
arterial hypertension. Direct renin inhibitors target the rate-limiting step in the RAS 
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cascade, preventing renin release, and before ACE inhibitors and ARBs in the cascade14. 
Studies in both animal and human models have equally enumerated the superiority of 
direct renin inhibitors (DRIs) over other agents targeting other points in the RAS 
pathway15,16. 
An agent that inhibits renin enzyme will prevent its cleavage of angiotensinogen. Being 
the first enzymatic reaction in this pathway, this will block subsequent steps in the 
reaction pathway, and such agent would tend to exert a better control of hypertension17. 
Considerable research18,19 over three decades has not yielded the much needed 
breakthrough in the quest for direct renin inhibitor antihypertensive drugs. This is partly 
because of difficulties in development, identifying suitable agents with the required 
combination of high affinity for renin’s active site and sufficient bioavailability to permit 
chronic oral administration20-23. To date, only one synthetic drug aliskiren (59), approved 
by FDA in 2007 is in use as a direct renin inhibitor24.  
However, the enzyme renin remains a very important drug target since the enzyme is 
specific for only one substrate-angiotensinogen. These inhibitors would also tend to 
produce fewer side effects12. 
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3.1.4   Role of Natural Products in the Treatment of Hypertension 
Like other areas of human health, natural products have contributed greatly in the 
management of hypertension.  Some food-derived peptides25,26, have shown promising 
results in lowering high blood pressure. The omega-3 fatty acids (eicosanpentoic acid 
(60) and docosahexanoic acid (61) obtained from fish oils have been found to be possibly 
effective in hypertension when orally administered27. Garlic, has been shown to lower 
blood pressure, when eaten, due to its ability to relax smooth muscles, and cause the 
dilatation of blood vessels27. Hosseini and his colleagues discovered that aqueous garlic 
extract significantly lowered the serum level of ACE in diabetic and non diabetic rats28. 
Canola meal subjected to enzymatic proteolysis yielded inhibitory peptides that inhibited 
ACE with an IC50 values ranging from 18.1 to 82.5 µg protein ml-1(29). Enzymatic 
hydroxylates from flaxseed protein when investigated for in vitro inhibition of ACE and 
renin showed a concentration-dependent ACE inhibition with an IC50 values ranging 
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from 0.0275-0.151 mg ml-1(30). Milk derived bioactive peptides have also been shown to 
inhibit ACE in vitro31-33. 
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Studies on different extracts from plants including ethanolic extract of Rabdosia coetsa,  
have shown promising inhibitory activities of the RAS pathway, particularly ACE34-36. A 
review of natural products inhibitors of angiotensin converting enzyme (ACE) between 
1980 to 2000 shows that 321 species of plants and 158 natural substances inhibited the 
enzyme37. Screening of 20 plants used by traditional healers in South Africa also 
indicated some of the plants inhibited ACE by up to 97%38. 
It is important to note that despite the strategic importance of renin in the RAS cascade, 
and the huge amount of studies aimed at discovering DRI drugs, little success has been 
achieved, particularly in the area of natural product. This has made this current study 
interesting.  
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3.2      EXPERIMENTAL 
3.2.1   General conditions 
Renin inhibitory activities were measured spectrophotometrically using JASCO FP-
6300 spectrofluorimeter (Japan Spectroscopic Company, Tokyo, Japan). Human 
recombinant Renin Inhibitor Screening Assay Kit   was purchased from Cayman 
Chemicals (Ann Arbor, MI, USA). Other analytical grade reagents used in the renin 
bioassay were purchased from Fischer Scientific (Oakville, ON, Canada). 
3.2.2   Bioassay Procedure 
The eight compounds from N. latifolia were weighed in mg using Sartorius CP224S 
weighing balance, and each dissolved with equivalent volume of methanol to make 
1mg/ml dilution (Scheme 3.2) . Further dilutions were made with the tris-buffer, to give 
the respective concentrations for the assay. Screening for inhibition was initially done 
with 50 and 5 micrograms concentrations. This was followed by the determination of the 
IC50 values using 5, 25, 50, and 100 microgram concentrations respectively. All the four 
concentrations of the compounds in the bioassay study were duplicated. 
In vitro inhibition of the activity of human recombinant renin was conducted by 
fluorescence spectrometry using the Renin Inhibitor Screening Assay Kit as reported by 
Udenigwe, et al30. Briefly, the total assay volume of 190µl contained 10 µM Arg-
Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(Dabcyl)-Arg(renin substrate 
dissolved in dimethyl sulphoxide), human recombinant renin and the compounds in 50 
mM Tris-HCl buffer, pH 8.0, containing 100 mM NaCl. The Tris-HCl buffer was used 
instead of the compounds in the blank experiment. The renin substrate and compounds 
were mixed and pre-warmed to 37°C for 10 min to attain thermal equilibrium. Thereafter, 
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the reaction was initiated by adding human recombinant renin to the mixture; the increase 
in fluorescence intensity was monitored for 10 min in a JASCO FP-6300 
spectrofluorimeter (Japan Spectroscopic Company, Tokyo, Japan) equipped with a 
thermostated cell compartment that was maintained at 37°C using a circulatory water 
bath.  The spectrofluorimeter parameters were set as follows: excitation wavelength, 340 
nm; emission wavelength, 490 nm; excitation bandwidth, 5 nm; emission bandwidth, 10 
nm. The enzyme activity was expressed as reaction rate, arbitrary fluorescence intensity 
unit per min (FIU.min-1). Renin inhibitory activity of each compound was calculated 
using the Equation: 
 
Renin inhibition (%) = [(FIU.min-1(control) – FIU.min-1(sample)) / FIU.min-1(control)] × 100  
Where: 
(FIU.min-1) (control) = Fluorescence intensity unit per min for blank = Renin reaction 
rate in the absence of compounds. 
(FIU.min-1)(sample) = Fluorescence intensity unit per min for samples = Renin reaction 
rate in the presence of compounds. 
 
The IC50 values were determined using linear regression (Figs A-58-63). These IC50 
values of the duplicated experiments were used to calculate the mean and standard 
deviation.  
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Scheme 3.2. Flow chart of Renin Bioassay 
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3.3   RESULTS 
The IC50  values of the renin inhibitory activity of the compounds are shown in Table 
3.1. Compounds (45-46) and (48-51) displayed varying levels of renin inhibition, while 
compounds 47 and 52 did not exhibit any inhibition. The inhibitory activity of 
compounds (49), (45) and (48) were higher (11.26, 16.25 and 32.58 µM respectively), 
compared to the rest of the compounds in these bioassays. 
 
 
Table 3.1. IC50 values of compounds (45-52) in anti-renin assay 
 
Compounds                     IC50 (µM)* 
________________________________________________________________________ 
45 (Angustoline)        16.3 ± 0.5 
46 (Latifoliamide A)        72.0 ± 11.3 
47 (Latifoliamide B)        - 
48 (Latifoliamide C)        32.6 ± 2.0 
49 (Latifoliamide D)        11.3 ± 1.1 
50 (Latifoliamide E)        95.0 ± 6.9 
51 (Latifoliamide F)        94.5 ± 3.0 
52 (Latifoliamide G)        -
________________________________________________________________________ 
*IC50 value represents the concentration of compounds needed to inhibit 50% of the activity of Renin. ± 
represents the standard deviation. 
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3.4 DISCUSION 
The result presented above provides an insight in the search for DRI agents, 
particularly from natural product origin. The RAS cascade plays a crucial role in the 
regulation of blood pressure39,40. The importance of renin, the rate limiting enzyme in the 
cascade has been variously enumerated6,41-43. It has also been shown that suppression of 
the RAS after treatment with either ACE inhibitors or ARB remains incomplete44. 
Development of renin inhibitors has faced different challenges including high cost of 
synthesis, lack of appropriate animal models, and inadequate bioavailability41.  
Currently, only alkisiren approved by FDA in 2007 is in use as the first and only direct 
renin inhibitor45-47. A handful of studies have been done on renin inhibitory activity of 
various foods30,41-43,48-50. Some studies have equally looked at the inhibitory activities of 
some synthetic peptides51,52. Screening for rennin inhibition using synthetic analogues of 
plant compounds has also been studied53. This study looks at the inhibitory activities of 
compounds isolated from N. latifolia against renin. Information available to us from 
published data indicated that this was the first time alkaloids from N. latifolia were tested 
for renin inhibitory activity. Six of the isolates (49, 45, 48, 46, 51, 50) displayed 
inhibitory activities, while two (47, 52) were inactive in this bioassay (Fig. 3.1). The 
inhibition of the compounds was concentration dependent, exhibiting higher inhibition at 
higher concentration of compounds. Compounds 49, 45 and 48 displayed significant 
inhibition of renin with 1C50 values of 11.26, 16.25 and 32.58 µM respectively. 
Commercially purified soybean saponin inhibited human renin with an IC50 59.9 µg ml-
1(48), and oleic and linoleic acids isolated from rice inhibited renin with inhibition kinetics 
of 15.8 and 19.8 µM respectively41. Saori et al, isolated soybean renin inhibitor from soy 
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bean with an IC50 value of 30 µg ml -1(43), and extracts from two groups of minor 
legumes, inhibited renin with IC50 values of 0.27-0.42 and 0.67-1.75 mg ml-1 
respectively. Chemical analogues of sodium houttuynin derived from the plant 
Houttuynia cordata inhibited renin with IC50 values of 273, 195 and 44 µM respectively. 
From the forgoing, the inhibition pattern displayed by the compounds isolated from N. 
latifolia, particularly compounds 49, 45, and 48, exhibited anti-renin activity that is 
comparable to aforementioned natural products. Compounds 47 and 52 did not show any 
inhibition. However, this was an in vitro screening experiment. An in vivo study is 
warranted since these two environments are not identical. The spectrophotometer used in 
the experiment records fluorescence. The high level of inhibition exhibited by 
compounds 49 and 45 at a concentration of 50 µM resulted in the machine recording 
florescence at a negative value, which was interpreted as zero florescence. There was no 
standard in the experiment. Aliskiren, the only DRI so far licensed for use was not 
available when this study was done. Its IC50 is 0.6 nM. Further studies on structure-
activity relationship are warranted to identify the active pharmacophore responsible for 
the inhibitory activity, and to possibly improve their bioactivity. Essential hypertension is 
a chronic medical condition which requires a prolonged period of drug administration. 
Major part of the setbacks in the successful production of direct renin inhibitor agents has 
been the identification of agents with good bioavailability after oral administration. N. 
latifolia is a common herb that has been in use in folk medicine by different people in 
different parts of the world. Most parts of this plant (leaves, stem, fruits, and roots) have 
been reported to be edible54, and this could have pharmacokinetic benefit. Based on the 
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available bioactivity data, we assume that the antihypertensive activity of this plant might 
be due to the presence of alkaloids in the crude extract 
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CONCLUSIONS 
In summary, phytochemical studies on the crude methanolic extract of N. latifolia 
resulted in the isolation of eight compounds 45-52. The structures of these compounds 
were determined using spectroscopic methods. Compounds 46-52 were identified as new 
natural products, while compound 45 had been previously identified. Compounds 45, 46, 
48-51, showed a wide range of anti-renin activity. Compounds 49, 45 and 48 were found 
to be most potent, compared to the rest of the isolates. The bioactivity data compares 
favorably well with available studies on natural product renin inhibition. Careful 
examinations of structures (45-52) reveal that all of the compounds contain at least two 
nitrogen atoms in their structures. The renin inhibitory activities of these compounds 
might have resulted from this common functional group. Further pharmacokinetic and 
structure-activity relationship studies on these compounds would help determine their 
toxicity and bioavailability as well as the active pharmacophore required for renin 
inhibition. The various numbers of reactive groups in these compounds make them good 
candidates for possible reactions, whose product could be more active. Compounds 47 
and 52 were inactive. 
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APPENDIX: SPECTRAL DATA OF COMPOUNDS 
 
 
Figure A-1. 1H-NMR spectrum of latifoliamide E (50) in DMSO 
Figure A-2. 13-C spectrum of latifoliamde E (50) in CDCL3 
 
Figure A-3.DEPT 135 spectrum of latifoliamde E (50) in CDCL3 
 
Figure A-4. DEPT 90 spectrum of latifoliamde E (50) in CDCL3 
 
Figure A-5. COSY spectrum of latifoliamde E (50) in CDCL3 
Figure A-6. HSQC spectrum of latifoliamde E (50) in CDCl3 
 
Figure A-7. HMBC spectrum of latifoliamde E (50) in CDCl3 
 
Figure A-8. NOESY spectrum of latifoliamde E (50) in CDCl3 
 
 
Figure A-9. 1H-NMR spectrum of latifoliamide D (49) in DMSO 
 
Figure A-10. 13-C spectrum of latifoliamde D (49) in CDCl3 
 
Figure A-11.DEPT 135 spectrum of latifoliamde D (49) in CDCl3 
 
Figure A-12. COSY spectrum of latifoliamde D (49) in CDCl3 
 
Figure A-13. HSQC spectrum of latifoliamde D (49) in CDCl3 
 
Figure A-14. HMBC spectrum of latifoliamde D (49) in CDCl3 
 
 
Figure A-15. 1H-NMR spectrum of latifoliamide B (47) in CDCl3 
 
Figure A-16. 13-C spectrum of latifoliamde B (47) in CDCl3 
 
Figure A-17. DEPT 135 spectrum of latifoliamde B (47) in CDCl3 
 
Figure A-18. COSY spectrum of latifoliamde B (47) in CDCl3 
 
Figure A-19. HSQC spectrum of latifoliamde B (47) in CDCl3 
 
Figure A-20. HMBC spectrum of latifoliamde B (47) in CDCl3 
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Figure A-21. NOESY spectrum of latifoliamde B (47) in CDCl3 
 
 
Figure A-22. 1H-NMR spectrum of angustoline (45) in CDCl3 
 
Figure A-23. 13C spectrum of angustoline (45) in CDCl3 
 
Figure A-24. DEPT 90 spectrum of angustoline (45) in CDCl3 
 
Figure A-25. DEPT 135 spectrum of angustoline (45) in CDCl3 
 
Figure A-26. COSY spectrum of angustoline (45) in CDCl3 
 
Figure A-27. HSQC spectrum of angustoline (45) in CDCl3 
 
Figure A-28. HMBC spectrum of angustoline (45) in CDCl3 
 
Figure A-29. NOESY spectrum of angustoline (45) in CDCl3 
 
 
Figure A-30. 1H-NMR spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-31. 13C spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-32. DEPT 90 spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-33. DEPT 135 spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-34. COSY spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-35. HSQC spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-36. HMBC spectrum of latifoliamide A (46) in CDCl3 
 
Figure A-37. NOESY spectrum of latifoliamide A (46) in CDCl3 
 
 
Figure A-38. 1H-NMR spectrum of latifoliamide C (48) in CDCl3 
 
Figure A-39. 13C spectrum of latifoliamide C (48) in CDCl3 
 
Figure A-40. DEPT 90 spectrum of latifoliamide C (48) in CDCl3 
 
Figure A-41. DEPT 135 spectrum of latifoliamide C (48) in CDCl3 
 
Figure A-42. HSQC spectrum of latifoliamide C (48) in CDCl3 
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Figure A-43. HMBC spectrum of latifoliamide C (48) in CDCl3 
 
Figure A-44. NOESY spectrum of latifoliamide C (48) in CDCl3 
 
 
Figure A-45. 1H-NMR spectrum of latifoliamide G (52) in CDCl3 
 
Figure A-46. 13C spectrum of latifoliamide G (52) in CDCl3 
 
Figure A-47. COSY spectrum of latifoliamide G (52) in CDCl3 
 
Figure A-48. HSQC spectrum of latifoliamide G (52) in CDCl3 
 
Figure A-49. HMBC spectrum of latifoliamide G (52) in CDCl3 
 
 
Figure A-50. 1H-NMR spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-51. 13C-NMR spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-52. DEPT 90 spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-53. DEPT 135 spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-54. COSY spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-55. HSQC spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-56. HMBC spectrum of latifoliamide F (51) in CDCl3 
 
Figure A-57. N spectrum of latifoliamide F (51) in CDCl3 
 
 
Figure A-58. A graph of Percentage inhibition vs. conc. of 45  
 
Figure A-59. A graph of Percentage inhibition vs. conc. of 48  
 
Figure A-60. A graph of Percentage inhibition vs. conc. of 49  
 
Figure A-61. A graph of Percentage inhibition vs. conc. of 46  
 
Figure A-62. A graph of Percentage inhibition vs. conc. of 50  
 
Figure A-63. A graph of Percentage inhibition vs. conc. of 51  
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Figure A-2. 13-C spectrum of latifoliamde E (50) in CDCL3 
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Figure A-3.DEPT 135 spectrum of latifoliamde E (50) in CDCL3 
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Figure A-4. DEPT 90 spectrum of latifoliamde E (50) in CDCL3 
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       Figure A-5. COSY spectrum of latifoliamde E (50) in CDCL3 
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Figure A-6. HSQC spectrum of latifoliamde E (50) in CDCl3 
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          Figure A-7. HMBC spectrum of latifoliamde E (50) in CDCl3 
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       Figure A-8. NOESY spectrum of latifoliamde E (50) in CDCl3 
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Figure A-9. 1H-NMR spectrum of latifoliamide D (49) in DMSO 
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  Figure A-10. 13-C spectrum of latifoliamde D (49) in CDCl3 
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Figure A-11.DEPT 135 spectrum of latifoliamde D (49) in CDCl3 
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      Figure A-12. COSY spectrum of latifoliamde D (49) in CDCl3 
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                   Figure A-13. HSQC spectrum of latifoliamde D (49) in CDCl3 
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Figure A-14. HMBC spectrum of latifoliamde D (49) in CDCl3 
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Figure A-15. 1H-NMR spectrum of latifoliamide B (47) in CDCl3 
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 Figure A-16. 13-C spectrum of latifoliamde B (47) in CDCl3 
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Figure A-17. DEPT 135 spectrum of latifoliamde B (47) in CDCl3 
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     Figure A-18. COSY spectrum of latifoliamde B (47) in CDCl3 
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    Figure A-19. HSQC spectrum of latifoliamde B (47) in CDCl3 
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      Figure A-20. HMBC spectrum of latifoliamde B (47) in CDCl3 
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    Figure A-21. NOESY spectrum of latifoliamde B (47) in CDCl3 
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Figure A-22. 1H-NMR spectrum of angustoline (45) in CDCl3 
 
                                                                                                                                           
        114  114                                                                                                                                                       
 
 
 
  Figure A-23. 13C spectrum of angustoline (45) in CDCl3 
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Figure A-24. DEPT 90 spectrum of angustoline (45) in CDCl3 
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Figure A-25. DEPT 135 spectrum of angustoline (45) in CDCl3 
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Figure A-26. COSY spectrum of angustoline (45) in CDCl3 
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        Figure A-27. HSQC spectrum of angustoline (45) in CDCl3 
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      Figure A-28. HMBC spectrum of angustoline (45) in CDCl3 
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           Figure A-29. NOESY spectrum of angustoline (45) in CDCl3 
 
 
 
 
 
                                                                                                                                           
        121  121                                                                                                                                                       
 
 
Figure A-30. 1H-NMR spectrum of latifoliamide A (46) in CDCl3 
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  Figure A-31. 13C spectrum of latifoliamide A (46) in CDCl3 
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Figure A-32. DEPT 90 spectrum of latifoliamide A (46) in CDCl3 
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Figure A-33. DEPT 135 spectrum of latifoliamide A (46) in CDCl3 
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Figure A-34. COSY spectrum of latifoliamide A (46) in CDCl3 
 
 
 
 
 
                                                                                                                                           
        126  126                                                                                                                                                       
 
 
 
 
      Figure A-35. HSQC spectrum of latifoliamide A (46) in CDCl3 
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         Figure A-36. HMBC spectrum of latifoliamide A (46) in CDCl3 
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      Figure A-37. NOESY spectrum of latifoliamide A (46) in CDCl3 
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Figure A-38. 1H-NMR spectrum of latifoliamide C (48) in CDCl3 
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Figure A-39. 13C spectrum of latifoliamide C (48) in CDCl3 
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Figure A-40. DEPT 90 spectrum of latifoliamide C (48) in CDCl3 
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Figure A-41. DEPT 135 spectrum of latifoliamide C (48) in CDCl3 
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                            Figure A-42. HSQC spectrum of latifoliamide C (48) in CDCl3 
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                         Figure A-43. HMBC spectrum of latifoliamide C (48) in CDCl3 
 
 
 
 
                                                                                                                                           
        135  135                                                                                                                                                       
 
 
 
 
 
                          Figure A-44. NOESY spectrum of latifoliamide C (48) in CDCl3 
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Figure A-45. 1H-NMR spectrum of latifoliamide G (52) in CDCl3 
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 Figure A-46. 13C spectrum of latifoliamide G (52) in CDCl3 
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           Figure A-47. COSY spectrum of latifoliamide G (52) in CDCl3 
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          Figure A-48. HSQC spectrum of latifoliamide G (52) in CDCl3 
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          Figure A-49. HMBC spectrum of latifoliamide G (52) in CDCl3 
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 Figure A-50. 1H-NMR spectrum of latifoliamide F (51) in CDCl3 
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Figure A-51. 13C spectrum of latifoliamide F (51) in CDCl3 
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Figure A-52. DEPT 90 spectrum of latifoliamide F (51) in CDCl3 
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Figure A-53. DEPT 135 spectrum of latifoliamide F (51) in CDCl3 
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          Figure A-54. COSY spectrum of latifoliamide F (51) in CDCl3 
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        Figure A-55. HSQC spectrum of latifoliamide F (51) in CDCl3 
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            Figure A-56. HMBC spectrum of latifoliamide F (51) in CDCl3 
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     Figure A-57. N spectrum of latifoliamide F (51) in CDCl3 
 
 
 
  
                                                                                                                                           
        149  149                                                                                                                                                       
 
 
Figure A-58. A graph of Percentage inhibition vs. conc. of 45  
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Figure A-59. A graph of Percentage inhibition vs. conc. of 48  
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Figure A-60. A graph of Percentage inhibition vs. conc. of 49  
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Figure A-61. A graph of Percentage inhibition vs. conc. of 46  
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Figure A-62. A graph of Percentage inhibition vs. conc. of 50  
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Figure A-63. A graph of Percentage inhibition vs. conc. of 51  
 
 
